Liver News and Research

RSS

Warfarin may prevent liver failure in hepatitis C

The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

31 Jul 2008

Ultra-miniature bialy-shaped drug delivery particles

Ultra-miniature bialy-shaped particles - called nanobialys because they resemble tiny versions of the flat, onion-topped rolls popular in New York City - could soon be carrying medicinal compounds through patients' bloodstreams to tumors or atherosclerotic plaques.

29 Jul 2008

Alcohol linked to increased risk of perennial allergic rhinitis

There is a link between alcohol consumption and increased risk of perennial allergic rhinitis, according to a recent Danish study of 5,870 young adult women.

29 Jul 2008

Lawmakers agree to ban use of phthalates in toys

Lawmakers charged with finalizing the Consumer Product Safety Commission Reform Act agreed yesterday to include a provision that will ban phthalates from children's toys and childcare articles. The legislative action validates the concerns of scientists and parents who have been urging a ban, and will bring federal regulation in line with several states and leading retailers that have already taken action to remove phthalates from toys.

29 Jul 2008

FDA approves first generic divalproex sodium for the treatment of seizures, bipolar disorder and migraine headaches

The U.S. Food and Drug Administration today approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches.

29 Jul 2008

New therapy freezes out esophagus cancer

UT Southwestern Medical Center gastroenterologists are using a new method to freeze damaged cells in the esophagus, preventing them from turning cancerous.

29 Jul 2008

Limiting fructose may boost weight loss

One of the reasons people on low-carbohydrate diets may lose weight is that they reduce their intake of fructose, a type of sugar that can be made into body fat quickly, according to a researcher at UT Southwestern Medical Center.

29 Jul 2008

Structure and composition of hepatitis B virus now mapped

Using a newly developed method, Utrecht University researchers have mapped the structure and composition of the hepatitis B virus.

28 Jul 2008

Researchers disprove long-standing belief about HIV treatment

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the 'cocktail.'

27 Jul 2008

Sorafenib extends life of advanced liver cancer patients

Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug.

23 Jul 2008

Shocking new figures reveal the extent of Britain's alcohol problem

According to government figures revealed in the UK, six per cent of all hospital admissions are related to illness or injuries caused by alcohol.

22 Jul 2008

Notch protein helps human embryonic stem cells 'decide' their own fate

Researchers at Johns Hopkins have discovered that the Notch protein helps human embryonic stem cells 'decide' their own fate, a finding which may eventually be useful in programming cells for the development of stem cell therapies. Their results are reported in the May 2008 issue of Cell Stem Cell.

22 Jul 2008

Sale of liver disease therapeutic patents

IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.

17 Jul 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

Higher than average success rate reported for children receiving living donor transplants

Ninety-six per cent of children who have received liver transplants from living relations are still alive five years after surgery, according to research published in the July issue of the British Journal of Surgery.

17 Jul 2008

New ways of exploiting medicinal uses of cannabis

Research exploring new ways of exploiting the full medicinal uses of cannabis while avoiding unwanted side-effects will be presented to pharmacologists Tuesday, 15 July by leading scientists attending the Federation of European Pharmacological Societies Congress, EPHAR 2008.

From The University of Manchester 15 Jul 2008

Hormone replacement therapy and gallbladder disease

Use of hormone replacement therapy (HRT) increases the risk of gallbladder disease but the effects are less with HRT given in skin patches or gels compared with HRT given orally, according to a study published on BMJ.com today.

10 Jul 2008

Potential new way to prevent graft-versus-host disease

A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication for people who have had bone marrow transplants.

10 Jul 2008

Enzyme may explain how hepatitis C infection causes fatty liver

A key enzyme may explain how hepatitis C infection causes fatty liver - a buildup of excess fat in the liver, which can lead to life-threatening diseases such as cirrhosis and liver cancer, report University of Pittsburgh Graduate School of Public Health and School of Medicine researchers.

10 Jul 2008

Nanomaterials key to new strategies for blocking metastasis

A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.

9 Jul 2008